Vertex Pharmaceuticals (WBO:VRTX) Cash Flow for Dividends: €0 Mil (TTM As of Mar. 2026)


WBO:VRTX Vertex Pharmaceuticals Inc WBO:VRTX
91 GF Score
Price €435.40
GF Value €440.30
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Vertex Pharmaceuticals Cash Flow for Dividends?

Vertex Pharmaceuticals WBO:VRTX +0.52% 91 Cash Flow for Dividends is €0 Mil as of Mar. 2026. GuruFocus rates WBO:VRTX with a GF Score™ of 91/100 and a GF Value™ of €440.30 (Fairly Valued). The stock has 4 warning signs investors should review.

Vertex Pharmaceuticals's cash flow for dividends for the three months ended in Mar. 2026 was €0 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was €0 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Vertex Pharmaceuticals Cash Flow for Dividends Related Terms

Vertex Pharmaceuticals Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Vertex Pharmaceuticals's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vertex Pharmaceuticals Cash Flow for Dividends Chart

Vertex Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Vertex Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
WBO:VRTX
91GF Score
Vertex Pharmaceuticals Inc WBO:VRTX
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vertex Pharmaceuticals Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of €0 Mil mean?
Vertex Pharmaceuticals (WBO:VRTX) has a Cash Flow for Dividends of €0 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Vertex Pharmaceuticals and its competitors.
Is Vertex Pharmaceuticals' Cash Flow for Dividends too high?
Vertex Pharmaceuticals' current Cash Flow for Dividends is €0 Mil. Overall, Vertex Pharmaceuticals has a GF Score™ of 91/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vertex Pharmaceuticals' Cash Flow for Dividends compare to REGN and ALNY?
Vertex Pharmaceuticals' Cash Flow for Dividends of €0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Biotechnology company?
A good Cash Flow for Dividends depends on the Biotechnology industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Vertex Pharmaceuticals and its competitors. Vertex Pharmaceuticals's current Cash Flow for Dividends is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vertex Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vertex Pharmaceuticals (WBO:VRTX) is currently considered Fairly Valued. The stock's GF Value™ is €440.30, compared to a current price of €435.40 — trading 1.1% below its estimated fair value. The current Cash Flow for Dividends is €0 Mil. Vertex Pharmaceuticals' overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Vertex Pharmaceuticals (WBO:VRTX), the current Cash Flow for Dividends is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vertex Pharmaceuticals (WBO:VRTX) Overvalued in 2026?

Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued. The current stock price of €435.40 is trading 1.1% below its estimated GF Value™ of €440.30. GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.

Key valuation signals for WBO:VRTX:

  • Cash Flow for Dividends: €0 Mil
  • GF Value™: €440.30 vs. price of €435.40 (1.1% below fair value)
  • GF Score™: 91/100 with 4 warning signs

No single metric tells the full story. See the WBO:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vertex Pharmaceuticals Business Description

Address 50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
91GF Score

Get the complete analysis for WBO:VRTX

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€435.40
Price
€440.30
GF Value